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b-2 Microglobulin (b2M) is a low molecular weight protein located extracellular-
ly and associated with class 1 antigens of the major histocompatibility complex
and is considered a marker for disease activity in immune disorders. Cladribine
(2-chloro-2-deoxyadenosine, 2-CDA) is a potent lymphocytotoxic agent under
investigation in the treatment in MS patients.  As b2M levels may indicate in-
flammatory events in CNS we determined CSF-b2M and serum b2M levels in
patients with relapsing-remitting MS before and after cladribine treatment as
well as in a control group. There was a significant b2M decrease in sera but not
in CSF in MS patients after the cladribine treatment, associated with a slight but
significant clinical improvement measured by Kurtzkes Expanded Disability Sta-
tus Scale. We also found a significant decrease in sICAM-1 level in CSF but not in
sera in MS patients. The data support a role of cladribine in MS therapy and
deliver new information on cladribine immunological effects in MS patients.
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INTRODUCTION
Multiple sclerosis (MS) is one of the most common
demyelinating disorders of the central nervous sys-
tem (CNS). Its pathomechanism remains still un-
known. It is suspected to be of autoimmune nature
and many observations indicate involvement of T
lymphocytes [6, 9]. There is evidence that in the first
stages of the disease lymphocytes migrate from the
vascular bed across the damaged blood-brain barri-
er to the brain tissue and cause myelin destruction
[6, 9, 11]. The inflammatory response and conse-
quent demyelinating lesions lie in close relationship
with cerebral vessels, particularly the veins and
venules [20]. Moreover it has been confirmed that
perivascular inflammation is more widespread than
demyelinating plaques themselves, which suggests
altered functioning of cerebral endothelium in early
MS [20].
Leukocyte-endothelial interactions are regulated
by several adhesion molecules, including selectins,
integrins and molecules of the immunoglobulin su-
perfamily. Some of them, e.g. vascular cell adhesion
molecule (VCAM-1), appear on the surface of en-
dothelial cells only after activation by cytokines (in-
terleukin-1, interferon gamma, tumour necrosis fac-
tor), some are present on resting endothelium, like
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intercellular adhesion molecule (ICAM-1), but their
expression increases during inflammation. ICAM-1
and other members of the immunoglobulin super-
family are involved in strong leukocyte binding to
the endothelial cells and allow their transmigration.
Many investigators have found increased concentra-
tions of the soluble form of ICAM-1 in patients suf-
fering from MS [8, 9, 11] and correlated it with dis-
ease activity. This suggests that the expression of this
molecule is strictly implicated in the pathomecha-
nism of the disorder. Moreover, soluble forms of these
cell adhesion molecules are probably involved in the
negative feedback, reducing leukocyte-endothelium
adhesion and consequently their migration across
the vascular wall toward the inflamed brain tissue.
b-2 microglobulin (b2M) is a low molecular weight
protein located extracellularly and associated with
class 1 antigens of the major histocompatibility com-
plex. There are reports that strongly suggest its role
in the activation of the immune system [17]. b2M is
then considered a marker for disease activity in im-
mune disorders [1]. Its precise role in pathology re-
mains still unknown, but it is supposed that it may
be implicated in lymphocyte activation in MS. Pre-
vious studies showed b-2 microglobulin to be in-
creased in cerebrospinal fluid (CSF) and sera of these
patients [2, 5].
Cladribine (2-chloro-2-deoxyadenosine, 2-CDA) is
a potent lymphocytotoxic agent under investigation
in the treatment of MS patients, earlier successfully
used in hairy-cell-leukemia and other autoimmune
disorders therapy [3, 7, 15]. There is evidence that it
could be effective in reducing activity in both chron-
ic progressive MS and the relapsing-remitting form
of the disease [10, 18, 19]. The purpose of our pa-
per is to study the effect of cladribine treatment on
b-2 microglobulin and soluble intercellular adhesion
molecule 1 (ICAM-1) in patients with multiple scle-
rosis to increase the knowledge of immunological
consequences during this therapy.
MATERIAL AND METHODS
We studied 25 patients (age range 20 to 50 years,
17 females and 8 males) diagnosed as definite MS
according to Posers criteria [20]. All had the relaps-
ing-remitting form of the disease. They had 2.5 – 0.5
relapses within the last 2 years with an average dis-
ease duration of 4.5 – 2.2 years.
The patients were given 5 mg 2-CDA in one daily
subcutaneous injection for 5 days each in 6 monthly
courses.
None of them had been treated with immuno-
suppressive therapy 6 months before inclusion. A new
relapse was the cause of admission of all patients.
Paired CSF and serum samples were drawn from all
MS patients before therapy (during a relapse) and
on the day of the last injection of 2-CDA (during
another relapse in 4 patients and out of relapse in
21 of them). The disability status of MS patients was
determined by Kurtzkes expanded disability status
scale EDSS [12]
The control group consisted of 10 sex- and age-
matched patients (age range 20 to 50 years, 7 fe-
males and 3 males) from whom CSF was drawn to
exclude neurological disorders and who were then
diagnosed as tension type headache.
Both CSF and blood samples from MS patients
and controls were centrifuged at 1200 rev/min for
10 min and stored at 70°C. The concentration of
sICAM-1 in the CSF and serum  was measured by
ELISA method (sICAM-1 Quantitative Colorimetric
Sandwich ELISA, R&D Systems, USA). b-2 concentra-
tion in the CSF and serum was determined by b-2
microglobulin sandwich ELISA method [13]. IgG CSF
levels and IgG indices were determined as well.
Statistical analysis was carried out using Wilcox-
on test for matched pairs; p-values lower than 0.05
were considered significant; the Mann-Whitney U-test
was used for the comparison between the MS group
before treatment and controls.
RESULTS
The mean value of the EDSS score in MS patients before
treatment was 3.5 – 2.4. It decreased after the therapy
to a value of 2.7 – 2.1 and reached the limit of statisti-
cally significant difference (Table 1). There was also a
statistically significant decrease in CSF IgG concentra-
tion as well as in IgG index after the therapy with 2-
-CDA (Table 2). We observed a significant reduction of
b2M serum level and a decrease in the CSF sICAM-1
concentration after cladribine treatment (Table 3).
Table 1. Clinical status of MS patients (EDSS)  before
(a) and after (b) treatment
All MS patients (25) EDSS (a) EDSS (b)
3.5 – 2.4 2.7 – 2.1
p = 0.048
No relapse 3.6 – 2.3 2.6 – 1.8
after treatment (n=21) p = 0.03
Relapse 3.1 – 2.5 3.2 – 1.6
after treatment (n = 4)
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DISCUSSION
We found for the first time that after 2-CDA treat-
ment b2M level is significantly decreased in serum
of MS patients. However there was no difference
between MS patients and controls with respect to
serum and CSF b2M concentration.
These observations are in accordance with those
of Ott and colleagues [14] and in contrast with some
previous reports [4]. We conclude that b2M may be
useful in evaluation of 2-CDA treatment in MS pa-
tients and cannot be considered a specific diagnos-
tic marker for MS.
Since we did not find any elevation of b2M CSF/
serum ratio (it ranged from 0.38 to 0.48 and was
slightly lower than that reported by Adachi [1]) and
noting that b2M is a very low molecular weight pro-
tein which easily passes through the blood-brain
barrier, it is likely that b2M presence in CSF is due to
its transudating from blood rather than to its intrath-
ecal synthesis. This is consistent with the finding that
a significant decrease in b2M level was found only in
serum but not in CSF.
An inverse observation was made when measur-
ing sICAM-1 levels. In contrast to some previous re-
ports [8, 9,11] we did not find a significant differ-
ence between sICAM-1 concentration in MS patients
compared with controls. Nevertheless, we found for
the first time a significant decrease in CSF sICAM-1
level after 2CDA treatment only in the group of pa-
tients without relapse after the therapy, but not in
sera in either group of patients (with or without re-
lapse at the end of the treatment). Noting that sI-
CAM-1 reflects the expression of its cell-bound form
(ICAM-1), which is involved in leukocyte trafficking
across the blood-brain barrier, it seems that a signif-
icant reduction of sICAM-1 may be a result of the
downregulated expression of ICAM-1.
Table 3. b-2 microglobline (b2M) and sICAM1 before (a) and after (b) treatment in MS patients
b2M mg/l (a) b2M mg/l (b) sICAM1 ng/ml (a) sICAM1 ng/ml (b)
Mean (range) Mean (range) Mean (range) Mean (range)
MS (25) 0.76 0.60 4.33 1.65
CSF (02.65) SD= 0.67 (03.03) SD= 0.69 (018.5) SD = 4.2 (08.4) SD = 2.0
p = 0.0036
Without relapse 0.74 0.61 4.42 1.60
after treatment (02.48) SD = 0.61 (02.64) SD = 0.58 (017.2) SD = 3.6 (08.1) SD = 1.8
(n = 21)
Relapse 0.77 0.59 4.30 4.1
after treatment (02.65) SD = 0.69 (03.03) SD = 0.62 (018.5) SD = 4.4 (08.4) SD = 4.3
(n = 4)
MS (25) 1.7 1.54 412.8 371.8
Serum (0.882.92) SD = 0.54 (04.49) SD = 0.95 (230.5598.3) SD = 98.6 (49.5761.1) SD = 154.9
p = 0.046
Without relapse 1.68 1.39 413.1 389.2
after treatment (0.882.85) SD = 0.50 (0.53.94) SD = 0.82 (230.5597.4) SD = 96.8 (49.5735.3) SD = 131.0
(n = 21) p = 0.038
Relapse 1.72 1.70 408.6 400.8
after treatment (0.752.92) SD = 0.60 (04.49) SD = 2.62 (241.2598.3) SD = 412.8 (67.4761.1) SD = 406.4
(n = 4)
Controls (10) 0.8 4.61
CSF (0.11.58) SD = 0.6 (1.5917.8) SD = 4.74
Controls (10) 1.61 432
Serum (0.13.1) SD = 0.96 (201863) SD = 222
Table 2. CSF IgG concentration and IgG index before (a)
and after (b) treatment in MS patients and control group
IgGa IgGb IgG index (a) IgG index (b)
(mg%) (mg%) Mean – SD Mean – SD
Mean – SD Mean – SD
All MS 5.17 – 3.67 4.81 – 2.35 1.11 – 0.75 1.01 – 0.59
patients
(n = 25)
Control 2.5 – 0.9 0.5 – 0.09
group p = 0.01 p = 0.01
(n = 10)
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The EDSS improvement that we observed during
the study is in accordance with other investigators
results [18, 19]. We found a similar reduction of the
EDSS score in our MS patients, as did Grieb and col-
leagues [10]. The findings support a role of cladrib-
ine in MS therapy and deliver new information about
cladribine immunological effects in MS patients, but
further studies on that subject are necessary.
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